Hepatitis C treatment outcome in relation to alcohol consumption and racial differences in southeastern Taiwan

Journal of the Formosan Medical Association

Volumn 114, Issue 11, 2015, Pages 1069-1075

  Lin, Ching Chung ^a,b,c   Wu, Chia Hsien ^a   Chen, Huan Lin ^a   Lin, I Tsung ^a   Chen, Ming Jen ^a,b,c   Wang, Tsang En ^a,b,c   Wang, Horng Yuan ^a,b,c   Shih, Shou Chuan ^a,b,c   Bair, Ming Jong ^a,d,e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d MEIHO UNIVERSITY   (Taiwan)

^e NATIONAL TAITUNG UNIVERSITY   (Taiwan)

Author keywords

Alcohol; Genotype; Hepatitis C; Race

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ANCESTRY GROUP; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; MALE; NONABORIGINAL PEOPLE; RACE DIFFERENCE; SUSTAINED VIROLOGICAL RESPONSE; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ADVERSE EFFECTS; AGED; COMBINATION DRUG THERAPY; DRINKING BEHAVIOR; ETHNOLOGY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ALCOHOL DRINKING; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TAIWAN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84951905152     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2014.03.001     Document Type: Article

References (24)

1. Singal A.K., Anand B.S. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007, 41:761-772.
2. Bellentani S., Pozzato G., Saccoccio G., Crovatto M., Croce L.S., Mazzoran L., et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999, 44:874-880.
3. Wiley T.E., McCarthy M., Breidi L., McCarthy M., Layden T.J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998, 28:805-809.
4. Lin H.H., Wang L.Y., Shaw C.K., Cheng M.L., Chung W.K., Chiang H.J., et al. Combined effects of chronic hepatitis virus infections and substance-use habits on chronic liver diseases in Taiwanese aborigines. J Formos Med Assoc 2002, 101:826-834.
5. Ohnishi K., Matsuo S., Matsutani K., Itahashi M., Kakihara K., Suzuki K., et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996, 91:1374-1379.
6. Bruggmann P., Dampz M., Gerlach T., Kravecz L., Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend 2010, 110:167-171.
7. Liu C.H., Liu C.J., Lin C.L., Liang C.C., Hsu S.J., Yang S.S., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
8. Babor T., Caetano R., Casswell S., Edwards G., Giesbrecht N., Graham K., et al. Alcohol: no ordinary commodity: research and public policy 2003, Oxford University Press, New York.
9. Ho C.S., Tsai A.C. Prevalence of overweight and obesity and its associated factors in aboriginal Taiwanese: findings from the 2001 National Health Interview Survey in Taiwan. Asia Pac J Clin Nutr 2007, 16:572-579.
10. Wang T.N., Huang M.C., Chang W.T., Ko A.M., Tsai E.M., Liu C.S., et al. G-2548A polymorphism of the leptin gene is correlated with extreme obesity in Taiwanese aborigines. Obesity 2006, 14:183-187.
11. Okazaki T., Yoshihara H., Suzuki K., Yamada Y., Tsujimura T., Kawano K., et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994, 29:1039-1043.
12. Le Lan C., Guillygomarc'h A., Danielou H., Le Dréau G., Lainé F., Védeilhié C., et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol 2012, 56:334-340.
13. Anand B.S., Currie S., Dieperink E., Bini E.J., Shen H., Ho S.B., et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006, 130:1607-1616.
14. Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008, 47:1884-1893.
15. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
16. Yu M.L., Huang C.F., Huang J.F., Chang N.C., Yang J.F., Lin Z.Y., et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13.
17. Huang C.F., Dai C.Y., Huang J.F., Chuang W.L., Yu M.L. Linkage of hepatitis C viral genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011, 53:367-368.
18. Hung C.H., Lee C.M., Lu S.N., Lee J.F., Wang J.H., Tung H.D., et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003, 10:87-94.
19. Yang S.S., Lai M.Y., Chen D.S., Chen G.H., Kao J.H. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int 2003, 23:426-433.
20. Liang C.M., Hu T.H., Lu S.N., Hung C.H., Huang C.M., Wang J.H., et al. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat 2013, 20:761-769.
21. Hsu S.J., Hsu C.S., Liu C.H., Liu C.J., Chen C.L., Chen P.J., et al. HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. Antivir Ther 2011, 16:227-235.
22. Chen W.J., Loh E.W., Hsu Y.P., Chen C.C., Yu J.M., Cheng A.T. Alcohol-metabolising genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. Br J Psychiatry 1996, 168:762-767.
23. Peng G.S., Yin J.H., Wang M.F., Lee J.T., Hsu Y.D., Yin S.J. Alcohol sensitivity in Taiwanese men with different alcohol and aldehyde dehydrogenase genotypes. J Formos Med Assoc 2002, 101:769-774.
24. Chen W.J., Loh E.W., Hsu Y.P., Cheng A.T. Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines. Biol Psychiatry 1997, 41:703-709.